TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31525613
Drug: Psychoeducational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychoeducational intervention program (PIP) consisting of 12 weekly group sessions.
Study: 27500675
Drug: High-frequency intrapulmonary
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency intrapulmonary ventilation along with mineral water baths, inhalations, exercise therapy, manual massage, intake of extract maral root, and 'Yantar antiox' preparation.
Study: 27500675
Drug: Standard rehabilitative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard rehabilitative treatment without high-frequency intrapulmonary ventilation.
Study: 15817723
Drug: Glycerol ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol ingestion (GI) - 37 ml water/l total body water plus 1.5 g glycerol/l total body water
Study: 15817723
Drug: Water ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water ingestion (WI) - 37 ml water/l total body water
Study: 30149898
Drug: CA125 (>35
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA125 (>35 U/mL) in postmenopausal women
Study: 30149898
Drug: HE4 (>140
Approvals — FDA: no, EMA: no, PMDA: no
Description: HE4 (>140 pmol/L) in postmenopausal women
Study: 30149898
Drug: HE4 (>70
Approvals — FDA: no, EMA: no, PMDA: no
Description: HE4 (>70 pmol/L) in premenopausal women
Study: 26123137
Drug: UFT 400
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT 400 mg/d (n=61)
Study: 24971988
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment with GnRH agonists
Study: 22695211
Drug: Nicorette(®) Microtab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorette(®) Microtab (tablet)
Study: 20157322
Drug: Family-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based behavioral treatment (intervention)
Study: 18310554
Drug: Proxy consent
Normalized name: proxyphylline
DrugBank: Proxyphylline (DB13449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxy consent for clinical trial enrollment (simvastatin treatment)
Study: 12808261
Drug: Cholesterol levels
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol levels below 240 mg/dl (6.20 mmol/L)
Study: 12808261
Drug: Cholesterol levels
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol levels below 220 mg/dl (5.68 mmol/L)
Study: 28817437
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy followed by gastrectomy with D1+ lymphadenectomy
Study: 22077962
Drug: 1% WBI-1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% WBI-1001 cream applied twice daily for 12 weeks
Study: 22077962
Drug: 1% WBI-1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% WBI-1001 cream
Study: 11863301
Drug: Aspirin treatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin treatment (400 mg, one dose daily for 3 days, starting 12 hours before the flight)
Study: 11863301
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) (one dose of enoxaparin injected between 2 and 4 hours before the flight, weight-adjusted 1,000 IU per 10 kg of body weight)
Study: 7877544
Drug: Pravastatin (20‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20‐40 mg/day)
Study: 2227075
Drug: Intravenous doxofylline
Normalized name: doxofylline
DrugBank: Doxofylline (DB09273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous doxofylline (100 mg as a single dose over 10 min)
Study: 2227075
Drug: Oral doxofylline
Normalized name: doxofylline
DrugBank: Doxofylline (DB09273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxofylline (400 mg given twice daily for 5 days)
Study: 1036709
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg raubasin
Study: 1036709
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg bencyclan
Study: 1036709
Drug: salt solution
Normalized name: Salt solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: salt solution (placebo)
Study: 30171497
Drug: Tipifarnib 300
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipifarnib 300 mg twice daily plus Erlotinib 150 mg once daily
Study: 29565149
Drug: Whole milk
Normalized name: Calcium fortified whole milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole milk (300 Kcals; G1) daily for 23 weeks
Study: 29565149
Drug: Fortified milk
Normalized name: Fortified milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified milk (300 Kcals; G2) daily for 23 weeks
Study: 19877976
Drug: Pill Placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill Placebo (PBO)
Study: 10229289
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to insulin therapy
Study: 8947995
Drug: Oral lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lithium carbonate (mean daily dose 437 +/- 185 mg, range 150-900 mg)
Study: 28817727
Drug: Oral lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lithium carbonate
Study: 2006773
Drug: Oral slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral slow-release theophylline (4.7 to 16.6 mg/kg/day, divided into two doses)
Study: 8688399
Drug: Ritodrine sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritodrine sustained release capsules (40 mg, 3 times a day for 7 days)
Study: 8688399
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (identical to ritodrine)
Study: 1839656
Drug: Isradipine 2.5
Normalized name: isradipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 2.5 mg or 5.0 mg/day
Study: 31607019
Drug: Ultrasound-guided erector
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided erector spinae block combined with oral drug pregabalin
Study: 31607019
Drug: Oral drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drug pregabalin
Study: 29394969
Drug: Lactulose plus
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose plus rifaximin 550 mg twice daily for 10 days
Study: 29394969
Drug: Lactulose alone
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose alone 30 ml thrice daily for 10 days
Study: 22170364
Drug: DASH diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DASH diet (28 g beef/d)
Study: 22170364
Drug: BOLD diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOLD diet (113 g beef/d)
Study: 22170364
Drug: BOLD+ diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOLD+ diet (153 g beef/d)
Study: 12792353
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor (PI) treatment
Study: 12792353
Drug: Non-protease inhibitor
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-protease inhibitor (non-PI) treatment
Study: 10577698
Drug: Standard radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard radiotherapy with carboplatin 70 mg/m2/day for 5 days during weeks 1 and 5 (R6C)
Study: 10577698
Drug: Accelerated radiotherapy
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated radiotherapy with carboplatin 70 mg/m2/day for 5 days during week 1 (R3C)
Study: 8950879
Drug: Alendronate (initially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (initially 5 mg daily, increased to 10 mg daily at 24 months)
Study: 6783861
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of beta-blockers and diuretic agents (Cardiotensin)
Study: 6783861
Drug: Sustained-release form
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release form of beta-blockers and diuretic agents
Study: 6783861
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of beta-blockers and diuretic agents
Study: 31490300
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone 10 mg/mL
Study: 31490300
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone 40 mg/mL
Study: 30886139
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with hemoglobin (Hb) ≥ 12 g/dl
Study: 30886139
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with hemoglobin (Hb) ≥ 12 g/dl including depth of response (and MRD)
Study: 22708608
Drug: Transdermal alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal alcohol concentration (TAC)
Study: 19477972
Drug: Occlusal adjustment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusal adjustment (treatment group)
Study: 17264719
Drug: Sevoflurane inhalation
Normalized name: Sevoflurane Inhalation Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane inhalation at 0.5-1 vol% end-tidal concentrations
Study: 11927756
Drug: Psychological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatment conditions (collapsed for this study)
Study: 9830233
Drug: Alendronate sodium
Normalized name: Alendronate Sodium
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate sodium 10 mg
Study: 2476624
Drug: Felodipine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (1 mg, intravenously)
Study: 26114854
Drug: 12 week
Normalized name: risedronate sodium 35 MG Oral Tablet, 12 Week Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 week multi-disciplinary lifestyle intervention (physical activity, nutrition education, cognitive behavioural therapy)
Study: 22146117
Drug: NLP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLP therapy
Study: 19203221
Drug: Bone marrow-derived
Normalized name: Allogeneic human bone marrow-derived mpc
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow-derived cells (BMC) therapy
Study: 16702369
Drug: Combination testing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination testing (carcinogenic HPV testing or cytology)
Study: 16702369
Drug: Combination testing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination testing
Study: 15274670
Drug: KC 11458
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: KC 11458 (8 mg t.d.s. for 8 days)
Study: 8214733
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no previous drug injected)
Study: 3446416
Drug: Salbutamol ointment
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol ointment (1% salbutamol base in white soft paraffin) b.d. for 2 weeks
Study: 30857385
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion during sevoflurane anesthesia
Study: 30857385
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion during sevoflurane anesthesia
Study: 25513965
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of ticagrelor (90 mg/bid) and warfarin
Study: 25513965
Drug: Triple antithrombosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antithrombosis therapy (clopidogrel + aspirin + warfarin)
Study: 16537707
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drug (NSAID) use
Study: 16537707
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drug (NSAID) non-use
Study: 8239849
Drug: Nabumetone, 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone, 1000 mg
Study: 8239849
Drug: Ibuprofen, 600
Normalized name: Ibuprofen, 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen, 600 mg four times daily
Study: 8239849
Drug: Ibuprofen plus
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen plus Misoprostol, 600 mg and 200 micrograms four times daily
Study: 3898700
Drug: Diazepam (0.185
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.185 mg/kg)
Study: 3898700
Drug: Diazepam (0.185
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.185 mg/kg) plus droperidol (0.09 mg/kg)
Study: 3898700
Drug: Diazepam (0.135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.135 mg/kg) plus droperidol (0.09 mg/kg)
Study: 22006202
Drug: tofacitinib 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 3 mg twice daily
Study: 22006202
Drug: tofacitinib 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 20 mg/day
Study: 18049022
Drug: 75 mg/day
Normalized name: Lyllana 0.075 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/day dipyridamole
Study: 18049022
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day dipyridamole
Study: 1618361
Drug: no antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: no antihypertensive therapy (control)
Study: 30686326
Drug: Robot-assisted reach
Normalized name: beach strawberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted reach training with guidance force (RT-G)
Study: 29272062
Drug: Intensive Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Insulin Treatment (IIT) - glargine/glulisine
Study: 29272062
Drug: Initial Combined
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial Combined Oral Antidiabetic Drug (COAD) therapy - glimepiride/metformin
Study: 24450500
Drug: High whey
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High whey protein, leucine-enriched supplement (20 g whey protein, 3g total leucine, 150 kcal)
Study: 22500661
Drug: Collagen hydrolysate
Normalized name: collagen, hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen hydrolysate 1200 mg/day
Study: 17573520
Drug: Prophylactic tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic tadalafil (10 mg)
Study: 17573520
Drug: Prophylactic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prophylactic dexamethasone (8 mg)
Study: 15964386
Drug: sirolimus, tacrolimus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: sirolimus, tacrolimus, low-dose rabbit antithymocyte globulin, and glucocorticoids
Study: 8537277
Drug: Lomefloxacin 400
Normalized name: lomefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin 400 mg once daily for 5 days
Study: 18324566
Drug: All subjects
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects (regardless of treatment condition)
Study: 15944869
Drug: Sibutramine 15
Normalized name: sibutramine 15 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 15 mg o. d. for 3 months
Study: 12886917
Drug: ondansetron (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (0.1 mg x kg‐1)
Study: 12886917
Drug: cyclizine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclizine (20 mg)
Study: 10391662
Drug: HDL-raising therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDL-raising therapy
Study: 1997698
Drug: Oral bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bacillus Calmette-Guerin (BCG)
Study: 6206321
Drug: Oral tocainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tocainide
Study: 27030325
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide 4 mg/day
Study: 22534712
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy methods applied during a monthly rehabilitation tour
Study: 22534712
Drug: Physical methods
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical methods of treatment
Study: 20367417
Drug: Low-dose teriparatide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose teriparatide (20 microg per day)
Study: 20367417
Drug: High-dose teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: High-dose teriparatide (40 microg per day)
Study: 8551532
Drug: Continuous vocalization
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous vocalization for 30 minutes after botulinum toxin injections
Study: 8551532
Drug: Vocal rest
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vocal rest for 30 minutes after botulinum toxin injections
Study: 3023276
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg three times daily)
Study: 29413434
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1200 mg, twice daily
Study: 22583627
Drug: Infrapatellar fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrapatellar fat pad-derived mesenchymal stem cell therapy combined with arthroscopic debridement and PRP injection
Study: 22583627
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (arthroscopic debridement and PRP injection without stem cells)
Study: 19915976
Drug: Hormonal treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal treatment for metastatic disease: yes
Study: 18555828
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT+)
Study: 18555828
Drug: No Hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Hormone Replacement Therapy (HRT-)
Study: 16866128
Drug: Control groups
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control groups receiving appropriate treatment
Study: 12627926
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 2 g in 50 ml of 0.9% sodium chloride
Study: 10528097
Drug: Two consecutive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two consecutive doses of 50 microg salbutamol inhaled via Turbuhaler
Study: 10528097
Drug: Two divided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two divided doses of 50 microg salbutamol inhaled via Turbuhaler with 1.5 min between doses
Study: 10528097
Drug: Therapeutic doses
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic doses of salbutamol via Turbuhaler
Study: 1884725
Drug: Nifedipine-ER tablets
Normalized name: nifedipine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine-ER tablets (once daily)
Study: 1884725
Drug: Nifedipine capsules
Normalized name: Nifedipine Capsules
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine capsules (t.d.s.)
Study: 1884725
Drug: Nifedipine-ER tablets
Normalized name: nifedipine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine-ER tablets
Study: 1884725
Drug: Nifedipine capsules
Normalized name: Nifedipine Capsules
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine capsules
Study: 6846300
Drug: Antacid tablets
Normalized name: Calcium Carbonate 500 MG Oral Tablet, Chewable [GOOD SENSE ANTACID TABLETS]
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid tablets (14 mEq neutralizing capacity per tablet)
Study: 28846633
Drug: Reconstituted freeze-dried
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconstituted freeze-dried strawberry beverage (50 g/day)
Study: 26244985
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus bevacizumab (176 patients)
Study: 26244985
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (194 patients)
Study: 26244985
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus bevacizumab (high LDH subgroup)
Study: 26244985
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (high LDH subgroup)
Study: 20337570
Drug: Indirect language
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect language therapy delivered by school staff using a consultancy model
Study: 20337570
Drug: Manualized language
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manualized language therapy delivered by speech and language therapists or assistants
Study: 19108423
Drug: Acupotomy-injection combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupotomy-injection combined with Feng's spinal manipulation (FSM)